Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study.
Bon G, Krasniqi E, Porru M, D'Ambrosio L, Scalera S, Maugeri-Saccà M, Di Lisa FS, Filomeno L, Arcuri T, Botticelli A, Santini D, Fabbri MA, D'Auria G, Pulito C, Blandino G, Marchiò C, Barba M, Ciliberto G, Vici P, Pizzuti L. Bon G, et al. Among authors: marchio c. Neoplasia. 2023 Nov;45:100937. doi: 10.1016/j.neo.2023.100937. Epub 2023 Sep 26. Neoplasia. 2023. PMID: 37769528 Free PMC article.
Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.
Ercolani C, Marchiò C, Di Benedetto A, Fabi A, Perracchio L, Vici P, Sperati F, Buglioni S, Arena V, Pescarmona E, Sapino A, Terrenato I, Mottolese M. Ercolani C, et al. Among authors: marchio c. J Exp Clin Cancer Res. 2017 Oct 13;36(1):143. doi: 10.1186/s13046-017-0613-2. J Exp Clin Cancer Res. 2017. PMID: 29029640 Free PMC article.
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Bon G, Pizzuti L, Laquintana V, Loria R, Porru M, Marchiò C, Krasniqi E, Barba M, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Barchiesi G, Mazzotta M, Marinelli D, Tomao S, Marchetti P, Valerio MR, Mirabelli R, Russo A, Fabbri MA, D'Ostilio N, Veltri E, Corsi D, Garrone O, Paris I, Sarobba G, Giotta F, Garufi C, Cazzaniga M, Del Medico P, Roselli M, Sanguineti G, Sperduti I, Sapino A, De Maria R, Leonetti C, Di Leo A, Ciliberto G, Falcioni R, Vici P. Bon G, et al. Among authors: marchio c. J Exp Clin Cancer Res. 2020 Dec 10;39(1):279. doi: 10.1186/s13046-020-01797-3. J Exp Clin Cancer Res. 2020. PMID: 33302999 Free PMC article.
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review.
Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, Molinelli C, Adamo V, Bianchini G, Biganzoli L, Curigliano G, De Laurentiis M, Fabi A, Frassoldati A, Gennari A, Marchiò C, Perrone F, Viale G, Zamagni C, Zambelli A, Del Mastro L, De Placido S, Guarneri V, Marchetti P, Puglisi F. Garutti M, et al. Among authors: marchio c. Cancers (Basel). 2022 Apr 9;14(8):1898. doi: 10.3390/cancers14081898. Cancers (Basel). 2022. PMID: 35454806 Free PMC article. Review.
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST.
Fiorino E, Merlini A, D'Ambrosio L, Cerviere I, Berrino E, Marchiò C, Giraudo L, Basiricò M, Massa A, Donini C, Leuci V, Rotolo R, Galvagno F, Vitali L, Proment A, Ferrone S, Pisacane A, Pignochino Y, Aglietta M, Grignani G, Mesiano G, Sangiolo D. Fiorino E, et al. Among authors: marchio c. Int J Mol Sci. 2022 Sep 8;23(18):10368. doi: 10.3390/ijms231810368. Int J Mol Sci. 2022. PMID: 36142281 Free PMC article.
197 results